Samsung Bioepis Is Latest To Move Ustekinumab Into Phase III
Joins A Slew Of Other Biosimilar Developers Jostling For Position On Stelara
Samsung Bioepis has become the latest firm to move an ustekinumab biosimilar into Phase III trials, with the firm’s SB17 proposed Stelara rival kicking off a study in plaque psoriasis patients.
You may also be interested in...
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
Bio-Thera has joined the ranks of biosimilars developers that have rivals to Stelara in Phase III trials, after kicking off a study for its BAT2206 proposed version of ustekinumab.
Alvotech has announced two studies running in parallel for the firm’s AVT04 ustekinumab biosimilar referencing Janssen’s $7.7bn Stelara treatment for autoimmune diseases, including a Phase III comparative study.